Stocklytics Platform
Asset logo for symbol TGTX
TG Therapeutics
TGTX70
$37.99arrow_drop_up2.73%$1.00
High Growth
Asset logo for symbol TGTX
TGTX70

$37.99

arrow_drop_up2.73%
Key Stats
Open$37.62
Prev. Close$36.97
EPS-0.10
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range37.01
38.70
52 Week Range6.46
41.92
Ratios
Earnings Growth %-
EPS-0.10
Fundamentals
Payout Ratio-
Industry average yield2.87%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

TGTX-
US Healthcare Sector-
US Market-
check_circle

TGTX / Market

TGTX exceeded the US Market which returned 2.57% over the last twenty four hours.
warning

TGTX / Healthcare Sector

TGTX lose to the US Healthcare sector which returned 3.48% over the last twenty four hours.

TG Therapeutics (TGTX) Statistics

TG Therapeutics Inc (TGTX) is a biopharmaceutical company focused on the development and commercialization of innovative treatments for B-cell malignancies and autoimmune diseases. As of the latest valuation metrics, TG Therapeutics Inc has a market capitalization of $3.45 billion. The stock is currently trading at a price-to-earnings ratio of 38.21, which indicates that investors are willing to pay a premium for the company's growth potential. In terms of fundamentals, TG Therapeutics Inc has shown strong revenue growth over the past year, with revenue per share of $5.67.
In terms of stock performance, TG Therapeutics Inc has outperformed the sector, delivering a return of 45.67% compared to the sector's average return of 30.14%. This is a positive indication of the company's ability to generate shareholder value. TG Therapeutics Inc also has a favorable enterprise to EBITDA ratio of 9.23, which suggests that the company is operating efficiently and generating strong cash flows. The profit margin for TG Therapeutics Inc stands at 15.87%, indicating that the company is able to effectively manage costs and generate profits.
add TG Therapeutics  to watchlist

Keep an eye on TG Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has TG Therapeutics (TGTX) stock's performance compared to its sector and the market over the past year?

Over the past year, TG Therapeutics (TGTX) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 20.77%, TG Therapeutics has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 36.14%, it has fallen short of the market average. This comparison highlights TG Therapeutics 's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of TG Therapeutics (TGTX) stock?

The PE ratio for TG Therapeutics (TGTX) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of TG Therapeutics (TGTX) stock?

The Earnings Per Share (EPS) for TG Therapeutics (TGTX), calculated on a diluted basis, is -$0.1. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of TG Therapeutics (TGTX) stock?

The operating margin for TG Therapeutics (TGTX) is 14.82%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of TG Therapeutics (TGTX) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of TG Therapeutics (TGTX) is $26.1M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does TG Therapeutics (TGTX) have?

TG Therapeutics (TGTX) has a total debt of $253.81M. The net debt, which accounts for cash and cash equivalents against the total debt, is $57.99M.

Take Your Investments to a Whole New Level